TY - JOUR
T1 - Impact of lobular versus ductal histology on overall survival in metastatic breast cancer
T2 - a French retrospective multicentre cohort study
AU - Dalenc, Florence
AU - Lusque, Amélie
AU - De La Motte Rouge, Thibault
AU - Pistilli, Barbara
AU - Brain, Etienne
AU - Pasquier, David
AU - Debled, Marc
AU - Thery, Jean Christophe
AU - Gonçalves, Anthony
AU - Desmoulins, Isabelle
AU - Levy, Christelle
AU - Uwer, Lionel
AU - Ferrero, Jean Marc
AU - Eymard, Jean Christophe
AU - Mouret-Reynier, Marie Ange
AU - Patsouris, Anne
AU - Frenel, Jean Sébastien
AU - Petit, Thierry
AU - Chevrot, Michael
AU - Bachelot, Thomas
AU - Guiu, Séverine
N1 - Publisher Copyright:
© 2022 Elsevier Ltd
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Background: The impact of the histological lobular subtype on overall survival (OS) in metastatic breast cancer (MBC) is still under debate, with very few data available. Patients and methods: Using the French national multicentre Epidemiological Strategy and Medico Economics [ESME]) data platform, the primary objective was to compare the OS of patients with invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) MBC, with adjustment on the main prognostic factors using two approaches: multivariable analysis and matching with a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1) and describe patients and tumour characteristics. Results: Of the 16,703 patients with MBC in the ESME database, 13,111 met all inclusion criteria for the present analysis. One-thousand eight-hundred and four (13.8%) patients had ILC and 11.307 (86.2%) IDC. In the multivariable analysis, patients with ILC had a worse OS [hazard ratio (HR): 1.31; 95%CI 1.20–1.42; p < 0.0001] and a worse PFS1 (HR: 1.15; 95%CI 1.07–1.22; p < 0.0001) as compared with those with IDC, independently of hormone receptor and HER2 status. Interestingly, OS was better (HR 0.79; 95% confidence interval [CI] 0.64–0.98; p = 0.0302), worse (HR: 1.17; 95%CI 1.08–1.27; p = 0.0001) or similar (HR: 0.88; 95%CI 0.67–1.15; p = 0.3455) in patients with ILC with triple-negative, hormone receptor-positive/HER2-negative and HER2-positive MBC, respectively, compared with patients with IDC. Conclusion: Lobular histology is an independent adverse prognostic factor among women with MBC. ILC MBC could be considered a specific entity. Dedicated prospective studies are needed to tailor the management of these patients.
AB - Background: The impact of the histological lobular subtype on overall survival (OS) in metastatic breast cancer (MBC) is still under debate, with very few data available. Patients and methods: Using the French national multicentre Epidemiological Strategy and Medico Economics [ESME]) data platform, the primary objective was to compare the OS of patients with invasive lobular carcinoma (ILC) versus invasive ductal carcinoma (IDC) MBC, with adjustment on the main prognostic factors using two approaches: multivariable analysis and matching with a propensity score. Secondary objectives were to compare first-line progression-free survival (PFS1) and describe patients and tumour characteristics. Results: Of the 16,703 patients with MBC in the ESME database, 13,111 met all inclusion criteria for the present analysis. One-thousand eight-hundred and four (13.8%) patients had ILC and 11.307 (86.2%) IDC. In the multivariable analysis, patients with ILC had a worse OS [hazard ratio (HR): 1.31; 95%CI 1.20–1.42; p < 0.0001] and a worse PFS1 (HR: 1.15; 95%CI 1.07–1.22; p < 0.0001) as compared with those with IDC, independently of hormone receptor and HER2 status. Interestingly, OS was better (HR 0.79; 95% confidence interval [CI] 0.64–0.98; p = 0.0302), worse (HR: 1.17; 95%CI 1.08–1.27; p = 0.0001) or similar (HR: 0.88; 95%CI 0.67–1.15; p = 0.3455) in patients with ILC with triple-negative, hormone receptor-positive/HER2-negative and HER2-positive MBC, respectively, compared with patients with IDC. Conclusion: Lobular histology is an independent adverse prognostic factor among women with MBC. ILC MBC could be considered a specific entity. Dedicated prospective studies are needed to tailor the management of these patients.
KW - Invasive ductal carcinoma
KW - Invasive lobular carcinoma
KW - Metastatic breast cancer
KW - Overall survival
UR - http://www.scopus.com/inward/record.url?scp=85124457338&partnerID=8YFLogxK
U2 - 10.1016/j.ejca.2021.12.031
DO - 10.1016/j.ejca.2021.12.031
M3 - Article
C2 - 35176614
AN - SCOPUS:85124457338
SN - 0959-8049
VL - 164
SP - 70
EP - 79
JO - European Journal of Cancer
JF - European Journal of Cancer
ER -